Purpose: Many patients with non-small cell lung cancer (NSCLC) are eligible only for palliative radiation (RT) at presentation. This study was designed to assess the feasibility of adding the anti-EGFR monoclonal antibody nimotuzumab to palliative thoracic RT.
Methods: Patients with stage IIB, III or IV NSCLC considered unsuitable for radical radiation or chemo-radiation received nimotuzumab weekly 8× (100, 200 or 400 mg) with radiation (30 or 36 Gy in 3 Gy fractions). If response or disease stability was observed, nimotuzumab was continued every other week starting from week 10 until progression or toxicity.
Results: Eighteen patients were enrolled: 6 at 100 mg, 7 at 200 mg, 5 at 400 mg nimotuzumab. Patient characteristics included median age 69 years, 11 males, 17 smokers, 17 Caucasians, stage IIIA/IIIB/IV 2/7/9, 5 Eastern Cooperative Oncology Group performance status (PS) 2; 9 adenocarcinoma. The most commonly reported adverse events were fatigue, anorexia, chills, pain and hypophosphatemia (grades 1 to 2 in most patients). No severe skin or allergic toxicity was noted. No dose-limiting toxicity was encountered. Objective response rate and disease control rate inside the radiation field were 66 and 94.0%, respectively.
Conclusion: Nimotuzumab administered concurrently with palliative thoracic radiation is well tolerated at each of the three doses investigated in NSCLC patients unsuitable for radical treatment. The low toxicity and absence of rash make this combination therapeutically attractive for frail patients with other co-morbidities and poor performance status. These results support further testing of this regimen in the phase II setting.